Inhibition of Disease Progression in Hepatitis C-Infected Patients With Compensated Liver Cirrhosis.

Trial Profile

Inhibition of Disease Progression in Hepatitis C-Infected Patients With Compensated Liver Cirrhosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 09 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 27 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top